Join Growin Stock Community!

Avalo therapeutics, inc.AVTX.US Overview

US StockHealthcare
(No presentation for AVTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AVTX AI Insights

AVTX Overall Performance

AVTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AVTX Recent Performance

-

Avalo therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AVTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AVTX Key Information

AVTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AVTX Profile

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Price of AVTX

AVTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AVTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1687.36
PB Ratio
3.54
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
54.69%
Net Margin
-52019.79%
Revenue Growth (YoY)
-76.59%
Profit Growth (YoY)
-92.96%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1687.36
PB Ratio
3.54
Price-to-FCF
-
Gross Margin
54.69%
Net Margin
-52019.79%
Revenue Growth (YoY)
-76.59%
Profit Growth (YoY)
-92.96%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is AVTX's latest earnings report released?

    The most recent financial report for Avalo therapeutics, inc. (AVTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AVTX's short-term business performance and financial health. For the latest updates on AVTX's earnings releases, visit this page regularly.

  • How is AVTX's revenue growth?

    In the latest financial report, Avalo therapeutics, inc. (AVTX) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does AVTX have?

    At the end of the period, Avalo therapeutics, inc. (AVTX) held Total Cash and Cash Equivalents of 27.05M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is AVTX's EPS continuing to grow?

    According to the past four quarterly reports, Avalo therapeutics, inc. (AVTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AVTX?

    Avalo therapeutics, inc. (AVTX)'s Free Cash Flow (FCF) for the period is -16.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 41.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AVTX?

    The latest valuation data shows Avalo therapeutics, inc. (AVTX) has a Price-To-Earnings (PE) ratio of -2.8 and a Price/Earnings-To-Growth (PEG) ratio of -0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.